Stock ScreenerStock IdeasZen Ratings + Top AnalystsStocks With a Zen Rating of A + Top Analyst consensus of Strong Buy + Large Upside in Target Price: Sep 7, 2025The 2 best sources of winning stocks is the Zen Ratings and our analysis of Top Analysts from Wall Street. Now we have combined them together in a best of both worlds approach to find stocks with the best upside potential.
Stock ScreenerStock IdeasZen Ratings + Top Analysts
Zen Rating: A
Upside/Downside: Large Upside
Top Analysts Consensus: Strong Buy
| Ticker | Company | Zen Rating | Growth | Market Cap | Revenue | EBITDA | Earnings | EPS | Rev. Y/Y | Rev. 5Y | Earn. Y/Y | Earn. 5Y | Earnings Date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | A | B | $688.27B | $53.26B | $18.75B | $13.80B | $15.35 | 36.83% | 18.34% | 88.34% | 19.92% | 2025-10-30 |
| RYAAY | RYANAIR HOLDINGS PLC | A | B | $32.19B | $15.67B | $3.44B | $1.81B | $3.29 | 3.75% | 9.94% | -13.09% | 19.70% | 2025-11-03 |
| WIX | WIXCOM LTD | A | B | $8.56B | $1.87B | $173.72M | $166.27M | $2.99 | 13.04% | 17.06% | 128.24% | N/A | |
| BGC | BGC GROUP INC | A | A | $4.71B | $2.58B | $404.32M | $152.66M | $0.31 | 21.27% | 3.91% | 24.00% | 59.53% | 2025-11-06 |
| IHS | IHS HOLDING LTD | A | B | $2.44B | $1.73B | N/A | $110.87M | $0.34 | -5.40% | N/A | N/A | N/A | |
| DBD | DIEBOLD NIXDORF INC | A | C | $2.19B | $3.67B | $275.40M | -$12.90M | -$0.34 | N/A | N/A | N/A | N/A | 2025-11-06 |
| FIVN | FIVE9 INC | A | A | $2.06B | $1.11B | $98.42M | $8.83M | $0.13 | 14.21% | 24.42% | N/A | N/A | |
| ARDT | ARDENT HEALTH PARTNERS INC | A | B | $1.88B | $6.20B | $541.00M | $254.86M | $1.86 | 10.03% | N/A | 169.57% | N/A | |
| NTCT | NETSCOUT SYSTEMS INC | A | B | $1.77B | $822.68M | -$294.85M | -$366.92M | -$5.12 | -0.82% | -1.60% | N/A | N/A | 2025-10-23 |
| BCRX | BIOCRYST PHARMACEUTICALS INC | A | A | $1.74B | $557.51M | $63.44M | -$35.71M | -$0.18 | 45.85% | 62.51% | N/A | N/A | 2025-10-29 |
| AVDL | AVADEL PHARMACEUTICALS PLC | A | A | $1.53B | $221.08M | $7.86M | -$2.92M | -$0.03 | 132.35% | 35.98% | N/A | N/A | 2025-11-05 |
| GBX | GREENBRIER COMPANIES INC | A | C | $1.46B | $3.53B | $541.60M | $228.90M | $7.33 | 0.70% | 2.85% | 85.57% | 23.13% | 2025-10-23 |
| DCO | DUCOMMUN INC | A | B | $1.35B | $789.82M | $98.47M | $35.16M | $2.37 | 3.02% | 1.81% | 94.26% | -3.62% | 2025-11-05 |
| LMB | LIMBACH HOLDINGS INC | A | B | $1.25B | $552.92M | $63.54M | $35.30M | $3.10 | 8.06% | -0.29% | 31.91% | 113.43% | 2025-11-05 |
| EVER | EVERQUOTE INC | A | C | $859.51M | $615.25M | $54.06M | $46.55M | $1.30 | 92.91% | 15.40% | N/A | N/A | |
| NRDS | NERDWALLET INC | A | B | $795.79M | $734.90M | $51.20M | $29.50M | $0.39 | 24.20% | N/A | N/A | N/A | 2025-10-29 |
| AKBA | AKEBIA THERAPEUTICS INC | A | A | $777.40M | $184.91M | $10.87M | -$45.31M | -$0.22 | -1.24% | -12.02% | N/A | N/A | 2025-11-06 |
| TBPH | THERAVANCE BIOPHARMA INC | A | A | $702.54M | $77.21M | $48.42M | $13.03M | $0.25 | 24.49% | 0.11% | N/A | N/A | 2025-11-05 |
| KMDA | KAMADA LTD | A | C | $410.59M | $169.52M | $34.21M | $19.01M | $0.33 | 9.67% | 5.21% | 17.86% | -7.60% | |
| ELMD | ELECTROMED INC | A | C | $204.30M | $64.00M | $11.32M | $7.54M | $0.89 | 16.97% | 14.53% | 48.33% | 12.22% |
Upgrade to Premium to View More
Use the proven Zen Ratings quant model to find stocks with high potential to beat the market. Stocks Zen-Rated "A" have beaten the market by +32.52% annually. Learn More
Already have access to Premium? Sign In
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.